title: [Bisphosphonates and bone remodeling: effectiveness in Paget's disease, fibrous dysplasia and osteoporosis].
abstract: Paget's disease of bone, bone fibrous dysplasia and osteoporosis are characterized by abnormal bone remodeling, and frequently imply intervention of orthopedists. Recent significant medical therapeutics improvements have been obtained with the use of bisphosphonates. Theses drugs decrease bone remodeling. In Paget's disease, bisphosphonates relieve bone pain, allow lytic areas refilling and decrease complications risk with normal bone formation. In fibrous dysplasia, bone pain is alleviated, osteolytic areas are refilled and cortices are widened. In postmenopausal osteoporosis, bisphosphonates increase bone mineral density, and reduce very significantly the subsequent risk of vertebral, femoral and lower forearm fractures. Bisphosphonates are a breakthrough in Paget's disease of bone, fibrous dysplasia of bone and osteoporosis.
authors: Service de Rhumatologie et de Pathologie Osseuse, Hôpital Edouard Herriot, Lyon.
authors: R
authors: R
authors: Chapurlat
authors: P J
authors: PJ
authors: Meunier
mesh_terms: D015519:Bone Density / Q000187:drug effects; D016723:Bone Remodeling / Q000187:drug effects*; D002118:Calcium / Q000378:metabolism*; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D005357:Fibrous Dysplasia of Bone / Q000188:drug therapy*; D050723:Fractures, Bone / Q000517:prevention & control; D006801:Humans; D010001:Osteitis Deformans / Q000188:drug therapy*; D010014:Osteolysis / Q000188:drug therapy; D010024:Osteoporosis / Q000188:drug therapy*; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy; D012307:Risk Factors
chemical_list: D004164:Diphosphonates; D002118:Calcium